诊断实验室服务

Search documents
Labcorp (LH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
ZACKS· 2025-07-24 18:30
Core Insights - Labcorp Holdings (LH) reported revenue of $3.53 billion for the quarter ended June 2025, marking a year-over-year increase of 9.5% and exceeding the Zacks Consensus Estimate of $3.49 billion by 1.14% [1] - The company's EPS for the same period was $4.35, up from $3.94 a year ago, and also surpassed the consensus EPS estimate of $4.14 by 5.07% [1] Financial Performance Metrics - The net book-to-bill ratio for Labcorp was 1.1%, matching the two-analyst average estimate [4] - Revenue from Biopharma Laboratory Services was $784.8 million, exceeding the average estimate of $743.2 million by four analysts, representing an 11% year-over-year increase [4] - Revenue from Diagnostics Laboratories was $2.75 billion, slightly above the estimated $2.74 billion, reflecting an 8.9% year-over-year change [4] - Adjusted Operating Income for Diagnostics Laboratories was reported at $482.8 million, compared to the average estimate of $466.41 million [4] - Adjusted Operating Income for Biopharma Laboratory Services was $123.3 million, exceeding the three-analyst average estimate of $117.62 million [4] - Unallocated corporate expenses were reported at -$74.5 million, better than the average estimate of -$78.99 million [4] Stock Performance - Labcorp's shares have returned -3.2% over the past month, contrasting with the Zacks S&P 500 composite's +5.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]